Sorted By Test Name - Mayo Medical Laboratories

DCRN
8847
Identification of patients most likely to benefit from antiplatelet therapy with aspirin or other agents may
be useful. Measurement of urinary 11-dTXB2 concentration may be used to assess an individual's platelet
activity and associated risk for developing cardiovascular events, as well as identify individuals most
likely to benefit from antiplatelet therapy. Urinary 11-dTXB2 offers an advantage over platelet-activation
markers measured in plasma or blood because it is not subject to interference from in vitro platelet
activation, which can easily occur as a result of local vein trauma or insufficient anticoagulation during
blood sample collection.
Useful For: Determining increased risk of coronary heart disease and stroke Identifying patients most
likely to benefit from antiplatelet therapy
Interpretation: Elevated baseline levels of 11-dehydro-thromboxane B2 (11-dTXB2) in patients may
indicate an increase in platelet activation and thrombosis resulting from atherosclerotic deposits or other
vascular obstructions. Patients that exhibit 11-dTXB2 values above the normal reference value may be at
increased risk for an ischemic cardiovascular event. Elevations of 11-dTXB2 in patients already receiving
anti-platelet therapy suggest a continued hypercoagulable state and alternative anti-thrombotic or
anti-platelet therapies should be considered.
Reference Values:
Males > or =18 years: 0-1,089 pg/mg of creatinine
Females > or =18 years: 0-1,811 pg/mg of creatinine
Reference values have not been established for patients that are 90% of
cases), with the third most common form of CAH (3-beta-steroid dehydrogenase deficiency,